The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Have a sex or relationship question? Ask Rachel about it using the form below or email [email protected] ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Ozempic has always come with side effects. The latest reported by users? Thinning hair and muscle loss. Experts break down ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The Trump administration is considering a shift in health care coverage, allowing Medicare and Medicaid to cover GLP-1 weight loss drugs.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.